A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. // Journal of Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S016882782602605X?dgcid=rss_sd_all
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma. Journal of Hepatology. https://www.sciencedirect.com/science/article/pii/S016882782602605X?dgcid=rss_sd_all
“A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.” Journal of Hepatology.
@article{article53545,
title = {A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma},
journal = {Journal of Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S016882782602605X?dgcid=rss_sd_all}
}